Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole

Jose F. Camargo, Danny Yakoub, Jeong Hee Cho-Vega

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Lipid formulations of amphotericin B remain the first-line antifungal therapy for invasive mucormycosis. Posaconazole is an alternative for salvage therapy, but its use as primary therapy is not recommended due to the paucity of clinical data. Here we describe the case of a 57-year-old diabetic woman receiving etanercept and prednisone for the treatment of psoriatic arthritis who developed primary cutaneous mucormycosis after a minor gardening injury. Infection was successfully treated with aggressive surgical debridement followed by a 6-week course of the new delayed-release tablet formulation of posaconazole and temporary withholding of anti-TNF treatment. Primary antifungal therapy with posaconazole can be considered in selected cases of cutaneous mucormycosis.

Original languageEnglish (US)
Pages (from-to)187-192
Number of pages6
JournalMycopathologia
Volume180
Issue number3-4
DOIs
StatePublished - Oct 13 2015
Externally publishedYes

Fingerprint

Mucormycosis
debridement
Debridement
mouth
therapeutics
Skin
prednisone
gardening
Gardening
amphotericin B
arthritis
Therapeutics
Salvage Therapy
Psoriatic Arthritis
Amphotericin B
Complementary Therapies
Prednisone
Tablets
posaconazole
Lipids

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Applied Microbiology and Biotechnology
  • Agronomy and Crop Science
  • veterinary (miscalleneous)

Cite this

Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole. / Camargo, Jose F.; Yakoub, Danny; Cho-Vega, Jeong Hee.

In: Mycopathologia, Vol. 180, No. 3-4, 13.10.2015, p. 187-192.

Research output: Contribution to journalArticle

@article{d96b026e43e04740b9e1826c97c2c116,
title = "Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole",
abstract = "Lipid formulations of amphotericin B remain the first-line antifungal therapy for invasive mucormycosis. Posaconazole is an alternative for salvage therapy, but its use as primary therapy is not recommended due to the paucity of clinical data. Here we describe the case of a 57-year-old diabetic woman receiving etanercept and prednisone for the treatment of psoriatic arthritis who developed primary cutaneous mucormycosis after a minor gardening injury. Infection was successfully treated with aggressive surgical debridement followed by a 6-week course of the new delayed-release tablet formulation of posaconazole and temporary withholding of anti-TNF treatment. Primary antifungal therapy with posaconazole can be considered in selected cases of cutaneous mucormycosis.",
author = "Camargo, {Jose F.} and Danny Yakoub and Cho-Vega, {Jeong Hee}",
year = "2015",
month = "10",
day = "13",
doi = "10.1007/s11046-015-9914-1",
language = "English (US)",
volume = "180",
pages = "187--192",
journal = "Mycopathologia",
issn = "0301-486X",
publisher = "Springer Netherlands",
number = "3-4",

}

TY - JOUR

T1 - Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole

AU - Camargo, Jose F.

AU - Yakoub, Danny

AU - Cho-Vega, Jeong Hee

PY - 2015/10/13

Y1 - 2015/10/13

N2 - Lipid formulations of amphotericin B remain the first-line antifungal therapy for invasive mucormycosis. Posaconazole is an alternative for salvage therapy, but its use as primary therapy is not recommended due to the paucity of clinical data. Here we describe the case of a 57-year-old diabetic woman receiving etanercept and prednisone for the treatment of psoriatic arthritis who developed primary cutaneous mucormycosis after a minor gardening injury. Infection was successfully treated with aggressive surgical debridement followed by a 6-week course of the new delayed-release tablet formulation of posaconazole and temporary withholding of anti-TNF treatment. Primary antifungal therapy with posaconazole can be considered in selected cases of cutaneous mucormycosis.

AB - Lipid formulations of amphotericin B remain the first-line antifungal therapy for invasive mucormycosis. Posaconazole is an alternative for salvage therapy, but its use as primary therapy is not recommended due to the paucity of clinical data. Here we describe the case of a 57-year-old diabetic woman receiving etanercept and prednisone for the treatment of psoriatic arthritis who developed primary cutaneous mucormycosis after a minor gardening injury. Infection was successfully treated with aggressive surgical debridement followed by a 6-week course of the new delayed-release tablet formulation of posaconazole and temporary withholding of anti-TNF treatment. Primary antifungal therapy with posaconazole can be considered in selected cases of cutaneous mucormycosis.

UR - http://www.scopus.com/inward/record.url?scp=84941259140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941259140&partnerID=8YFLogxK

U2 - 10.1007/s11046-015-9914-1

DO - 10.1007/s11046-015-9914-1

M3 - Article

VL - 180

SP - 187

EP - 192

JO - Mycopathologia

JF - Mycopathologia

SN - 0301-486X

IS - 3-4

ER -